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Viral hepatitis is the most common form of hepatitis caused by A, B, C, D, and E virus. Viral hepatitis poses a major public health problem in the world with a death rate of 
1.35 million deaths each year [1]. Although there is a paucity in 
the data of national disease burden, viral hepatitis shares a total 
of 3% among the communicable diseases burden to India [1]. 
Hepatitis A and E cause acute viral hepatitis (AVH), whereas 
B and C can cause chronic viral hepatitis, in addition to acute 
infection [2]. Hepatitis A and E are transmitted through feco-oral 
route, whereas the B and C are transmitted through parenteral 
route. Hepatitis B is preventable with the vaccine; however, there 
is no vaccine for hepatitis C [3]. The treatment of hepatitis A virus 
and hepatitis E virus is usually symptomatic and supportive, no 
specific antiviral treatment required for them [4]. In recent times, 
silymarin, interferon, and nucleoside analogues are practiced in 
the treatment of AVH [5].
In Ayurveda, hepatitis or jaundice is acknowledged as 
Kamala roga, caused due to impairment of pitta dosha and rakta 
dhatu. The condition occurs due to Kostha gata Pitta, Pitta Rakta 
dusti, and Yakrit asrita Pitta dusti. In this condition, aggravated 
pitta dosha further vitiates rakta and mamsa and produces Kamala. 
It has two variations, namely Kosthasrita Kamala/Bahu pitta 
Kamala and Sakhasrita Kamala. The chronic form of Kamala 
leads to Kumbha Kamala, halimaka, panaki roga. The diagnosis 
of Kamala consisting of an evaluation of the types of Kamala 
through examination of skin, mucous membrane, and stool color. 
Assessment of Agni, Bala, Dosha vriddhi, Dhatus involvement 
is required to decide the therapeutic measures. In Kosthasrita 
Kamala, Tikta rasa (drugs with bitter taste) prayoga and virechana 
are recommended. However, in Sakhasrita Kamala, Kaphahara 
treatment is required at initial stages to bring the pitta dosha from 
Sakha (skin and periphery) to Kostha (alimentary canal) [6]. Few 
studies have also proved the efficacy of Ayurvedic medicines in 
hepatobiliary disorders [7,8].
A detail documentation of the efficacy and safety of the 
Ayurvedic drug on Kamala has not yet reported distinctly. Hence, 
in the present communication, we are presenting a case of AVH 
(Kamala), intervened successfully with two Ayurvedic medicines 
on the basis of Ayurvedic principles.
CASE REPORT
A 20-year-old male of the suburban area of Bhubaneswar presented 
with loss of appetite, flatulence, low-grade fever, malaise, and 
yellowish discoloration of urine of the 3 days duration. He had 
a normal bowel habit, without any history of abdominal pain, 
dysuria, or vomiting. There was neither any history of any 
medication taken by him in the past 3 months nor any history 
of an epidemic of jaundice reported from the habitation of the 
patient. The patient was a college student and did not reveal any 
habit of smoking, alcohol consumption, blood transfusion, drug 
abuse, and hemodialysis. None of his family has any significant 
medical illness.
On examination, the patient had a general weakness and 
fatigue. He had a 38°C temperature with stable vital signs. Mild 
icteric tint detected on the sclera and undersurface of the tongue. 
However, pallor, edema, abdominal swelling, palmar erythema, 
pruritus, and weight loss were not observed. On abdominal 
ABSTRACT
Acute viral hepatitis (AVH) has resemblance with Kamala mentioned in Ayurveda. Kamala is a disease of the Raktavaha srotas 
(a system which includes liver, spleen, blood vessels, and reticuloendothelial tissue) and dominant of pitta dosha. Nitya virechana 
(regular use of mild laxative) and Pitta samana is the principles to treat the condition in Ayurveda. Here, we report the case 
of a 20-year-old male diagnosed with AVH treated in accordance to the Ayurvedic principles reported, that is, Mridu virechana 
(regular use of mild laxatives), and Pitta samana. The total duration of the treatment including follow-up was 60 days. A complete 
remission of symptoms with a substantial reduction in bilirubin and hepatic enzymes observed following Ayurvedic treatment. 
Hence, presenting this case is an evidence to demonstrate the effectiveness of Ayurvedic treatment in AVH. 
Key words: Acute viral hepatitis, Avipattikar churna, Hyperbilirubinemia, Jaundice, Kamala
Ratha and Meher Management of acute viral hepatitis through Ayurveda - A case report
Vol 4 | Issue 6 | Nov - Dec 2018 Indian J Case Reports 512
examination, moderate tender on epigastrium and mild tender 
hepatomegaly without any splenomegaly observed. No other any 
abnormality discovered through systemic examination. From 
the Ayurvedic perspective, the patient had nausea, yellowish 
discoloration of eyes, and dark urine with a normal stool color. 
Agnimadya (anorexia), pitta vriddhi, Madhyama Bala, Pitta 
Kapha Prakriti also observed in the case.
The baseline investigation report showed that liver enzymes 
were elevated: Serum glutamic-oxaloacetic transaminase 
[SGOT] - 314.7 IU/L and serum glutamic-pyruvic transaminase 
[SGPT] - 323.4 IU/L; hyperbilirubinemia (total serum 
bilirubin - 4.83 mg/dl and direct bilirubin - 2.40 mg/ dl) 
with normal alkaline phosphatase 28.8 IU/L. The other 
hematological parameters were normal (total white blood 
cells - 8100/ µL, hemoglobin - 14 g/dl, differential leukocyte 
count neutrophil - 41%, lymphocyte - 52%, eosinophil - 7%, and 
platelet count - 210,000/µL). The viral marker for hepatitis B 
surface antigen (HBsAg) was found negative and no hepatomegaly 
detected in the ultrasound of the whole abdomen.
From the presenting features (constitutional symptoms) and 
investigation (hyperbilirubinemia and elevated hepatic enzymes), 
the case was diagnosed as Bahu pitta Kamala or Kosthasrita 
Kamala (hepatocellular jaundice/AVH). The patient was assessed 
clinically and also through laboratory investigation to ensure 
the clinical status and recovery. The following drugs were 
prescribed to the patient: Trikatu, triphala, trivrit, clove, mustaka, 
and M-liv tablet. The pharmacological basis of the drugs was 
given in Table 1 9-14]. The patient was strictly adhered to the 
drugs and regimen advised to him. No any adverse effect or any 
untoward event reported by him during the course of therapy. The 
patient recovered gradually from fever, malaise, and yellowish 
discolored of urine within 1 week of the treatment. However, loss 
of appetite, flatulence, and general weakness continued until the 
end of the 3rd week. The icteric tint started disappearing at the 
end of 2nd week of the treatment and disappeared after 3rd week. 
Liver size became normal at the end of the 2nd week treatment. 
A reduction in liver enzyme levels seen from 2nd week onward 
(SGOT - 218.5 IU/L and SGPT - 231.8 IU/L) and significant 
drop noticed (SGOT - 29.45 IU/L and SGPT - 24.75 IU/L) after 
3 weeks of the treatment. Similarly, decrease in bilirubin level 
seen earlier, that is, from the 2nd week of therapy (total serum 
bilirubin - 2.91 mg/dl) and it became obsoletely normal (total 
serum bilirubin - 0.94 mg/dl) after 6 weeks of therapy. The other 
hematological parameters remain unchanged throughout the 
treatment period. No adverse effect of the prescribed drugs also 
observed in the case.
DISCUSSION
Kosthasrita Kamala, a disease caused due to vitiation of pitta 
dosha. Pitta dosha in normalcy is the responsible factor for proper 
digestion, metabolism, body complexion, maintenance of body 
temperature, and proper pigmentation of blood, urine and stool. In 
Kamala, the Yakritasrita Pitta is vitiated and its vimargagamana 
(regurgitation into blood) occurs. When intensified pitta gets T
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localized in Kostha, called Kosthasrita Kamala (hepatocellular 
jaundice), however, it affects Sakha (deeper Dhatus or tissues), 
when amalgamated with Kapha dosha (Sakhasrita Kamala/
obstructive jaundice). Stool becomes abnormal in color, when 
Kaphanubandha is there and pitta present in Sakha. However, 
stool appears normal in color, when Pitta restricted to Kostha only. 
The normal yellow color of stool disappears and it looks white 
(Tilapistanibhabarchah/Swetabarchah) due to vimargagamana 
of pitta dosha. Aggravated pitta causes derangement in digestion 
and its excess accumulation causes regurgitation in to the blood 
and produces yellowish discoloration of skin, urine, nails, Ajeerna 
(dyspepsia), Daurbalya (weakness), and anorexia (Aruchi) [15].
Kamala is a disease of Pitta and Raktadusti origin. As per 
Ayurveda, Yakrita is the moolasthana (origin) of rakta, and 
pitta is the mala of Rakta. Due to Ashrya-Ashrayisambhanda 
(interdependency), elimination of pitta through virechana is 
essential to treat Rakta Dusti, and Virechana with mridu and ruksha 
dravya is beneficial in Bahupitta Kamala. Reduction of pitta 
through regular virechana can reduce the intensity of yellowish 
discoloration and can bring rapid recovery. The Virechana karma 
told in Ayurvedic classics for the treatment of Kamala may also 
be helpful in the prevention of hepatic encephalopathy and early 
cessation of carrier stage of virus. Sakhasrita Kamala is initially 
treated with Katu rasa, Katu vipaka, and Ushna veerya drugs 
to remove the kapha avarodha. In Shakhagata Kamala (deep 
seated, in tissues), vriddha pitta begins to move toward Koshtha 
(gastrointestinal tract). Once the Pitta reaches the Koshtha, it 
recolors the stool. At this stage, the patient is treated with Tikta, 
Madhura rasa, Madhura vipaka, Sheeta veerya, and Anulomana 
drugs which will help in pacifying the vriddha pitta and mitigate 
the Kamala. Improvement in symptoms, disappearing of icterus, 
drop in hepatic enzymes level to normal range, and reduction in 
the bilirubin level at different intervals of the treatment indicate 
the resolving state of the hepatic dysfunction.
The description of AVH or hepatocellular jaundice (viral) is 
similar to the Ayurvedic description of Kamala. Viral hepatitis A 
and E are usually self-limited and recover after 4 weeks of onset. 
However, in very few cases, fulminating hepatic necrosis or 
hepatic encephalopathy occurs. Viral hepatitis always associated 
with hyperbilirubinemia and elevated liver enzymes (SGOT 
and SGPT). Jaundice is clinically observed when bilirubin 
in the blood exceeds 2.3 mg/dl [16]. In Bahu Pitta Kamala, 
strict observation of diet and lifestyle is important because 
Kaphavardhakaahara can cause agnimandya and produces 
samakapha, which can cause sanga (obstruction) of srotas and 
vimarga gamana of Raktasrita Pitta, that can leads to Sakhasrita 
Kamala. Apart from Samsodhanachikitsa, Samsamana of vitiated 
pitta dosha is essential through the drugs with Tikta and Madhura 
rasa dominance [17].
In the present case, since the patient was negative for HBsAg, it 
was diagnosed as AVH (either A or E - virus origin). Other medical 
conditions such as gastritis, malaria, urinary tract infection, and 
biliary colic came in ambit of diagnosis, which differentiated from 
the condition through normal urinalysis, complete blood count and 
negative (malaria parasite) antigen test. Ultrasound sonography 
test abdomen and pelvis was done to rule out obstructive 
pathology. The stool color of the patient was normal, and he 
was treated in the line of Bahupitta/Kosthasrita Kamala. He was 
advised for bed rest and prescribed with two Ayurvedic medicines 
(Avipattikara Churna and M-Liv tablet) from the hospital. All the 
medicines prescribed to him are endowed with Piitasamaka Rasa 
(Madhura, Tikta, and Kashaya), Madhura Vipaka, Sheeta Veerya, 
Anulomana, and mriduvirechaka properties. He further directed 
to avoid Pittavardhakaahara and Vihara such as stale/sour 
salty, spicy, oily food, and drinks and also instructed to maintain 
proper hygiene and sanitation at home. Herein, the Avipattikara 
churna possesses the properties of Pitta elimination through 
sukha virechana (mild laxative) and the ingredients of M-liv 
fulfilled the Pitta samana as well as hepatoprotection. There are 
few cases of viral hepatitis treated with classical and proprietary 
Ayurvedic reported earlier by some scholars. In this study, we 
found a significant drop in bilirubin and enzyme level observed 
only after 2nd and 3rd week of commencement of treatment. 
Similar observations have also reported earlier with multiple drug 
regimens in hepatitis patient  [18-20].
CONCLUSION
AVH is a major public health problem habitually with epidemic 
outbreaks. There is an ample scope to revalidate the Ayurveda 
and traditional medicine for the management of this disease. This 
case report endorses a step toward the revalidation of Ayurvedic 
medicine in AVH Kamala. Further, a well-structured clinical trial 
is recommended with an adequate sample size to establish the 
efficacy and safety.
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